Nitric Oxide (NO) inhibits coronavirus infection by altering spike protein binding and disrupting the virus's ability to attach to the receptor and infect human cells. It also inhibits coronavirus viral replication inside an infected cell by slowing viral RNA production.
FREMONT, CA: Life science incubator focused on using its extensive intellectual property portfolio in nitric oxide, KNOW Bio, generated the first definitive evidence that nitric oxide (NO) can inhibit viral reproduction of SARS-CoV-2, the human coronavirus that causes COVID-19. Nitric oxide is a molecule produced naturally by the body to regulate blood flow, control inflammation, and defend against invading microorganisms. The milestone in-vitro experiments were conducted by testing multiple nitric oxide-releasing compounds against wild type SARS-CoV-2 virus at an independent laboratory with a deep history of antiviral research. Therapeutic doses (<200 µM) were applied to infected VERO E6 cells and showed a dose-dependent viral replication effect. The result was a greater than 99.9 percent reduction in virus observed after 24 hours versus virus observed on untreated cells. Furthermore, there was no cytotoxic impact on uninfected cells.
"We are the first to confirm the potent biological activity of nitric oxide against SARS-CoV-2, the novel coronavirus that causes COVID-19," said Neal Hunter, Chief Executive Officer, KNOW Bio. "As a leader in the development of NO-based therapies, we felt we were best positioned to establish that NO is effective against this virus." The company's earlier reports have only speculated on the potential of nitric oxide to serve as a therapeutic for patients with COVID-19 or as a preventative countermeasure for those at risk of exposure to the virus. These conjectures were mainly based on prior published scientific evidence derived from studies on the original SARS-CoV virus.
"The expansive literature supporting nitric oxide's function as a broad-spectrum antimicrobial, shows that nitric oxide-based approaches can play a role in preventing, limiting, and/or treating the pulmonary consequences of COVID-19," said Mark Schoenfisch, Ph.D., Chief Scientific Officer, KNOW Bio.
Nitric Oxide (NO) inhibits coronavirus infection by altering spike protein binding and disrupting the virus's ability to attach to the receptor and infect human cells. It also inhibits coronavirus viral replication inside an infected cell by slowing viral RNA production - resulting in fewer RNA strands and viral copies. "We have gained new understandings into the effective concentrations, rates of release and mechanism of action of nitric oxide against human coronavirus - providing valuable insights into safety and efficacy," continued Schoenfisch.